Digital Microscope Review to Sort HPV-Positive Women in Cervical Cancer Screening in Cameroon
Tests digital cell review to triage HPV-positive women in cervical cancer screening.
Plain-language title generated from the registry record
Registry title: Digital Telecytology for Triage of HPV-Positive Women in Cameroon
Key facts
- Where
- Yaoundé, CameroonSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 50 years old?
Source: NCT07550010, who can take part
Where in Cameroon
- Centre Hospitalier Universitaire de YaoundéYaoundé, CameroonTaking people
- Yaoundé University Teaching Hospital (CHU)Yaoundé, CameroonTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Geneva
- Trial code
- NCT07550010
- Record updated
- 24 April 2026
- Original description
This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyping-based algorithm, including immediate treatment, telecytology triage, or follow-up. Histological assessment serves as the reference standard for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Secondary objectives include evaluation of AI-assisted telecytology and visual inspection with acetic acid (VIA), as well as the acceptability of screening and treatment strategies among women and healthcare providers. The study aims to generate evidence to support scalable, WHO-recommended test-triage-treat approaches in low-resource settingsRead full original descriptionShow less
Evaluation of Digital Cytology for the Triage of HPV-positive Women in a Same-day "Test-triage-treat" Cervical Cancer Screening Strategy in Cameroon
This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyping-based algorithm, including immediate treatment, telecytology triage, or follow-up. Histological assessment serves as the reference standard for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Secondary objectives include evaluation of AI-assisted telecytology and visual inspection with acetic acid (VIA), as well as the acceptability of screening and treatment strategies among women and healthcare providers. The study aims to generate evidence to support scalable, WHO-recommended test-triage-treat approaches in low-resource settings
Inclusion: HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old; Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF).
Exclusion: Previous hysterectomy; Known cervical cancer; Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass); Conditions that can interfere with visualization of the cervix; Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure); Pregnancy at the time of screening; Women who are not able to comply with the study protocol.